Pharmacological therapy remains a crucial strategy in managing pediatric supraventricular tachycardias, often allowing ablative techniques to be deferred to an age with fewer adverse effects and higher success rates.
Supraventricular tachycardias in children still remain a challenge not only for the pediatrician, but also for the adult cardiologist who is facing an infant in an emergency situation. This review examines the unique aspects of pediatric arrhythmias, with particular emphasis on acute treatment and pharmacological prophylaxis. All current treatment options are focused, from the “old drugs” to the “novel ablative techniques”: the first are often able to defer the second to a more suitable age, with fewer adverse effects and higher success rates. A brief account on Wolff-Parkinson-White issues concludes the review.
No takes yet. Share an insight, caveat, or question.
Bronzetti et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: